In vivo increase in thrombin generation by four‐factor prothrombin complex concentrate in apixaban‐treated healthy volunteers
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 13 (10) , 1799-1805
Abstract
No abstract availableKeywords
Funding Information
- Sanquin Blood Supply
- The alliance of Bristol-Myers Squibb and Pfizer
This publication has 27 references indexed in Scilit:
- Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteersJournal of Thrombosis and Haemostasis, 2014
- Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is ImminentCanadian Journal of Cardiology, 2014
- Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major BleedingCirculation, 2013
- A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNature Medicine, 2013
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With RivaroxabanStroke, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismNew England Journal of Medicine, 2013
- Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit ModelAnesthesiology, 2012
- Emergency Hospitalizations for Adverse Drug Events in Older AmericansNew England Journal of Medicine, 2011
- Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex ConcentrateCirculation, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011